rovalpituzumab tesirine: Clinical Trials

13 trials of rovalpituzumab tesirine, newest first

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

7 completed, 4 terminated, 1 no longer available, 1 withdrawn. 7 Phase 1, 5 Phase 2, 3 Phase 3.

By phase and status

Phase	Trials	Status
Phase 1	7	Completed 4, Terminated 3
Phase 2	5	Completed 3, Terminated 2
Phase 3	3	Completed 1, Terminated 1, Withdrawn 1

Follow rovalpituzumab tesirine: new trials by email Literature Review of rovalpituzumab tesirine trials Research Report on rovalpituzumab tesirine

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Long-Term Study of Rovalpituzumab Tesirine rovalpituzumab tesirine - Cancer	Phase 2	Completed	AbbVie	3	2018-09-10	2021-01-05
Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer Dexamethasone, Rovalpituzumab tesirine - Small Cell Lung Cancer	Phase 3	Withdrawn	AbbVie		2018-03-15	2018-12-26
A Study on the Safety and Tolerability of Rovalpituzumab Tesirine in Japanese Patients With Advanced, Recurrent Small Cell Lung Cancer Rovalpituzumab tesirine - Small Cell Lung Cancer	Phase 1	Completed	AbbVie	29	2017-04-28	2021-08-03
Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE) Rovalpituzumab tesirine, Topotecan, Dexamethasone - Small Cell Lung Cancer	Phase 3	Completed	AbbVie	444	2017-04-11	2021-02-23
A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer Ipilimumab, Nivolumab, Rovalpituzumab tesirine - Small Cell Lung Cancer	Phase 1 / Phase 2	Terminated	AbbVie	42	2017-03-30	2020-07-17
A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU) Placebo for dexamethasone, Placebo for rovalpituzumab tesirine, Rovalpituzumab tesirine - Small Cell Lung Cancer	Phase 3	Terminated	AbbVie	748	2017-02-07	2021-07-29
A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors Venetoclax, Rovalpituzumab Tesirine, ABBV-181 - Advanced Solid Tumors	Phase 1	Completed	AbbVie	182	2016-12-14	2022-04-14
A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Extensive Stage Small Cell Lung Cancer Rovalpituzumab Tesirine, Cisplatin, Etoposide - Small Cell Lung Cancer	Phase 1	Terminated	AbbVie	28	2016-10-01	2020-03-12
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors Rovalpituzumab tesirine, Dexamethasone - Malignant Melanoma, Medullary Thyroid Cancer	Phase 1 / Phase 2	Terminated	AbbVie	200	2016-09-23	2020-10-19
A Study of Rovalpituzumab Tesirine to Study Cardiac Ventricular Repolarization in Subjects With Small Cell Lung Cancer Rovalpituzumab Tesirine - Small Cell Lung Carcinoma	Phase 1	Completed	Stemcentrx	46	2016-09-01	2018-09-24
Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer Rovalpituzumab tesirine - Small Cell Lung Cancer	Phase 2	Completed	AbbVie	342	2016-01-25	2021-07-30
Rovalpituzumab Tesirine (SC16LD6.5) in Recurrent Small Cell Lung Cancer Rovalpituzumab tesirine (SC16LD6.5) - Recurrent Small Cell Lung Cancer	Phase 1 / Phase 2	Completed	Stemcentrx	82	2013-07-01	2018-08-09
Expanded Access to Rovalpituzumab Tesirine rovalpituzumab tesirine - Small Cell Lung Cancer		No longer available	AbbVie			2019-09-10

Conditions studied

Sponsors

Countries

Top investigators

Results publications

NIH funding